Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.57 |
| ▸ | MAOA | P21397 | 6/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | HPD | P32754 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042171 | 0.95 | MAOB (0.57) | MAOBMAOAGRM5CYP1A2ACHE | |
| SCHEMBL5040852 | 0.87 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL5044639 | 0.86 | MAOB (0.61) | MAOBMAOAGRM5ACHE | |
| SCHEMBL20905162 | 0.84 | MAOB (0.58) | MAOBMAOAGRM5NR4A2 | |
| SCHEMBL5044659 | 0.83 | GABRG2 (0.42) | MAOBMAOA | |
| SCHEMBL5045262 | 0.83 | MAOB (0.57) | MAOBMAOAGRM5NR4A2 | |
| SCHEMBL4425403 | 0.82 | MAOB (0.67) | MAOBMAOAGRM5CYP1A2ACHE | |
| SCHEMBL30468506 | 0.82 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL29051778 | 0.82 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL566484 | 0.82 | MAOB (0.56) | MAOBMAOAGRM5NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680127-B1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | claimed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | claimed |
| US-20050107360-A1 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-05-19 | — | — | US | claimed |
| EP-1680127-B1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070117791-A1 | Bicyclic compounds | JOLIDON SYNESE | 2007-05-24 | — | — | US | disclosed |
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2007-04-05 | — | — | US | disclosed |
| US-7173023-B2 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2006138475-A2 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | JENRIN DISCOVERY (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1680127-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| US-20050107360-A1 | Bicyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005039591-A1 | BENZAZEPINE DERIVATIVES AS MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078172-A1 | MAO-B INHIBITORS USEFUL FOR TREATING OBESITY | MAOB, MAOA, GPR119 | MAOB 1/4885MAOA 2/4885GRM5 744/4885 |
| US-20050107360-A1 | Bicyclic compounds | MAOB, MAOA, XDH | MAOB 1/4885MAOA 2/4885GRM5 797/4885 |
| US-20070117791-A1 | Bicyclic compounds | MAOB, MAOA, XDH | MAOB 1/4885MAOA 2/4885GRM5 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.